Derma Sciences Inc (DSCI)

4.77
0.05 1.10
NASDAQ : Health Care
Prev Close 4.72
Open 4.75
Day Low/High 4.75 / 4.75
52 Wk Low/High 2.85 / 6.81
Volume 1.52K
Avg Volume 53.40K
Exchange NASDAQ
Shares Outstanding 28.31M
Market Cap 141.53M
EPS -1.50
P/E Ratio 4.00
Div & Yield N.A. (N.A)

Latest News

Derma Sciences Names Russell Olsen President Of Advanced Wound Care

Derma Sciences Names Russell Olsen President Of Advanced Wound Care

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the appointment of Russell Olsen as President of Advanced Wound Care.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, ACM, ACTS, BID, CC, COH, COKE, DSCI, EGRX, FNV, NWS, SHO, SSNC Downgrades: AMBC, HHC, HLF, LXFR, ROG, TCP Initiations: APLE, CNXR, EKSO, GNL, HLTH, LIND Read on to get TheStreet Quant Ratings' detailed report:

Derma Sciences Reports 2016 Second Quarter Financial Results

Derma Sciences Reports 2016 Second Quarter Financial Results

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and six months ended June 30, 2016.

Derma Sciences To Hold Second Quarter Financial Results Conference Call On August 9th

Derma Sciences To Hold Second Quarter Financial Results Conference Call On August 9th

Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on August 9, 2016 to discuss the financial results for the...

Derma Sciences To Acquire BioD, Solidify Its Leadership Position In Advanced Wound Care And Regenerative Products

Derma Sciences To Acquire BioD, Solidify Its Leadership Position In Advanced Wound Care And Regenerative Products

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the signing of a definitive agreement to acquire BioD, LLC for an immediate transaction value of $21.

Derma Sciences To Sell First Aid Products Division For Approximately $12.2 Million

Derma Sciences To Sell First Aid Products Division For Approximately $12.2 Million

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the signing of a definitive agreement to sell its First Aid Division (FAD) to Dukal Corporation for...

Derma Sciences Reports 2016 First Quarter Financial Results

Derma Sciences Reports 2016 First Quarter Financial Results

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three months ended March 31, 2016.

Derma Sciences To Hold First Quarter Financial Results Conference Call On May 11th

Derma Sciences To Hold First Quarter Financial Results Conference Call On May 11th

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on May 11, 2016 to discuss the financial results for the first...

Derma Sciences Announces AMNIOEXCEL® Is Now Eligible For Reimbursement By Medicare Administrative Contractor CGS

Derma Sciences Announces AMNIOEXCEL® Is Now Eligible For Reimbursement By Medicare Administrative Contractor CGS

Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that CGS Administrators, LLC (CGS), a Medicare Administrative Contractor (MAC) for Parts A and B serving...

Derma Sciences Reports 2015 Fourth Quarter And Full Year Financial Results

Derma Sciences Reports 2015 Fourth Quarter And Full Year Financial Results

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and 12 months ended December 31, 2015.

Derma Sciences To Hold Fourth Quarter Financial Results Conference Call On March 16th

Derma Sciences To Hold Fourth Quarter Financial Results Conference Call On March 16th

Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on Wednesday, March 16, 2016 to discuss the financial results...

Findings From Multicenter Study Comparing Derma Sciences' AMNIOEXCEL® Against Standard-of-Care For Treating Diabetic Foot Ulcers Published In WOUNDS, A Leading Peer-Reviewed Journal

Findings From Multicenter Study Comparing Derma Sciences' AMNIOEXCEL® Against Standard-of-Care For Treating Diabetic Foot Ulcers Published In WOUNDS, A Leading Peer-Reviewed Journal

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that a peer-reviewed comparative clinical study of AMNIOEXCEL ® Amniotic Allograft Membrane plus...

Derma Sciences' AMNIOEXCEL® Now Eligible For Reimbursement By Medicare Administrative Contractor WPS

Derma Sciences' AMNIOEXCEL® Now Eligible For Reimbursement By Medicare Administrative Contractor WPS

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that WPS Government Health Administrators (WPS), a Medicare Administrative Contractor (MAC) for Part B...

Derma Sciences Provides 2015 Preliminary Net Sales And Introduces 2016 Financial Guidance

Derma Sciences Provides 2015 Preliminary Net Sales And Introduces 2016 Financial Guidance

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, provides preliminary net sales for the year ended December 31, 2015, announces various actions to reduce operating...

Derma Sciences Announces Leadership And CEO Transition

Derma Sciences Announces Leadership And CEO Transition

Derma Sciences, Inc. (NASDAQ:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that Stephen T.

Derma Sciences To Participate In The 27th Annual Piper Jaffray Healthcare Conference

Derma Sciences To Participate In The 27th Annual Piper Jaffray Healthcare Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Edward J.

Derma Sciences To Participate In The Canaccord Genuity 2015 Medical Technology & Diagnostics Forum

Derma Sciences To Participate In The Canaccord Genuity 2015 Medical Technology & Diagnostics Forum

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Edward J.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud By Derma Sciences, Inc. And Certain Officers And Directors

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud By Derma Sciences, Inc. And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of Derma Sciences, Inc.

Derma Sciences (DSCI) Stock Falls After Ending Drug Trial

Derma Sciences (DSCI) Stock Falls After Ending Drug Trial

Derma Sciences (DSCI) stock is plunging in mid-morning trading on Thursday, after the company ended Phase 3 trials for its diabetic foot ulcer healing treatment.

Derma Sciences Announces Results Of Futility Analyses For Phase 3 Clinical Trials Of Aclerastide In Diabetic Foot Ulcer Healing

Derma Sciences Announces Results Of Futility Analyses For Phase 3 Clinical Trials Of Aclerastide In Diabetic Foot Ulcer Healing

Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the termination of its Phase 3 clinical trials with aclerastide (DSC127) for diabetic foot ulcer healing.

Derma Sciences To Hold Conference Call On November 12 To Discuss Data Monitoring Committee Pre-Specified Interim Analysis Of The Aclerastide Phase 3 Trials

Derma Sciences To Hold Conference Call On November 12 To Discuss Data Monitoring Committee Pre-Specified Interim Analysis Of The Aclerastide Phase 3 Trials

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, will issue a news release at 7:30 a.

Derma Sciences Reports Third Quarter 2015 Financial Results

Derma Sciences Reports Third Quarter 2015 Financial Results

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and nine months ended September 30, 2015.

Derma Sciences To Hold Third Quarter Financial Results Conference Call On November 9th

Derma Sciences To Hold Third Quarter Financial Results Conference Call On November 9th

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on Monday, November 9, 2015 to discuss the financial results...

Derma Sciences Reports Second Quarter Financial Results

Derma Sciences Reports Second Quarter Financial Results

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and six months ended June 30, 2015.

Derma Sciences To Present At The Canaccord Genuity Global Growth Conference

Derma Sciences To Present At The Canaccord Genuity Global Growth Conference

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Edward J.

Derma Sciences To Hold Second Quarter Financial Results Conference Call On August 10th

Derma Sciences To Hold Second Quarter Financial Results Conference Call On August 10th

Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, announced today that it will hold a conference call on August 10, 2015 to discuss the financial results for the second...

Derma Sciences Announces Publication In Advances In Wound Care

Derma Sciences Announces Publication In Advances In Wound Care

Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the publication of a review of the current clinical development program for aclerastide (DSC127), a...

Derma Sciences Completes Non-Clinical Aclerastide Toxicology Program

Derma Sciences Completes Non-Clinical Aclerastide Toxicology Program

Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that the required two-year animal carcinogenicity study for aclerastide has produced "clean results"...